Bristol Claims A First With Opdivo In Neoadjuvant NSCLC
Co-Primary Endpoint Data May Support Early Approval
More lung cancer patients treated with neoadjuvant Opdivo plus chemotherapy had a pathologic complete response than those who received chemo alone. BMS will discuss the results with regulators.
You may also be interested in...
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.
The Celgene acquisition gave BMS a new top-selling drug but Revlimid revenue will start to decline as soon as next year and it is likely to take many new products to replace it.
Recent launches and products acquired with Celgene are helping BMS grow, CEO Caforio said, while Opdivo is moving toward resuming growth thanks to first-line NSCLC and other factors.